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ABSTRACT 
 
Background: This national prospective cohort study compared the patient-reported 
outcomes of breast cancer patients having post-mastectomy autologous reconstruction to 
those who had breast implants, in terms of aesthetic appearance, levels of psychological, 
physical and sexual well-being and overall satisfaction.  
Methods: Of 5,063 women who underwent immediate (IR; n=3,349) or delayed (DR; 
n=1,714) reconstruction between 1 January 2008 and 31 March 2009 in England, 2,923 
women who consented were sent validated, procedure-specific 18-month follow up 
questionnaires.  Outcome scale scores ranged from 0 (poor) to 100 (excellent); multiple 
linear regression was used to adjust scores for patient and treatment characteristics. 
Results: 2,289 women (78%) returned completed questionnaires (1,528 IR, 761 DR).  For 
IR, mean overall satisfaction scores for the various techniques ranged from 67 to 85 (median 
67 to 93).  For DR, mean overall satisfaction scores ranged from 70 to 85 (median 75 to 
100).  For both groups, similar gradients were observed for the other outcome scales across 
techniques.  Reconstruction using patients’ own tissues tended to have higher mean 
adjusted scores compared with those techniques using implants alone (p<0.0001 for 
aesthetic appearance, psychological well-being, sexual well-being, and satisfaction with 
outcomes for IR and DR groups).   
Conclusion: Women who underwent autologous reconstruction tended to report greater 
satisfaction than those who had an implant reconstruction.  These results can inform patients 
of the anticipated outcomes of their selected surgery but further research is required to 
confirm whether autologous reconstruction is superior in general. 
 
 
Keywords: Breast Neoplasms; Mastectomy; Breast Reconstruction; Outcome Measures; 
United Kingdom 
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Introduction 
 
Women who undergo mastectomy surgery for breast cancer can have their breast mound 
reconstructed in a variety of ways.1  All of the options aim to address the aesthetic impact of 
mastectomy and may also improve patients’ physical, emotional and sexual well-being.2  
There has been much debate regarding the best way to assess the effectiveness of different 
types of reconstructive procedures.3,4  Internationally, the consensus view has shifted 
towards the use of patient-reported outcome measures rather than anthropomorphic 
measurements or measurement scales scored by clinicians.2  This is in part because 
previous studies have found little correlation between clinician-reported and patient-reported 
aesthetic satisfaction following such surgery and partly because of a recognition that the 
patient should be the ultimate judge of subjective outcomes such as aesthetic appearance.5,6 
 
Numerous studies have evaluated patient-reported outcomes following different types of 
breast reconstruction in populations of between 45 and 2,328 women.6-15  However, these 
studies demonstrated methodological weaknesses in one or more of the following areas: 
inadequate length of follow up; a failure to include immediate reconstruction (IR) and 
delayed reconstruction (DR) patients, the full range of reconstructive techniques, and all 
eligible centres; lack of a prospective design; a lack of case-mix adjustment; a lack of 
validated and surgery-specific scales; and a failure to formally calculate outcome scores for 
these scales to enable valid comparisons.   
 
We undertook a national prospective cohort study that examined patient-reported outcomes  
after mastectomy and breast reconstruction surgery for women treated in England, Scotland 
and Wales.16  The study collected data from women having IR or DR procedures using a set 
of validated surgery-specific scales that have been used widely to evaluate the outcomes of  
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breast reconstruction.2,17  In this paper, we compare the outcomes of six different 
reconstructive techniques. 
 
Methods 
 
Treatment sites and inclusion criteria 
During the 15 month recruitment period from 1 January 2008 to 31 March 2009, all 150 
English NHS acute hospital trusts providing acute breast cancer treatment, six NHS acute 
trusts in Wales and Scotland, and 114 independent hospitals in England participated in the 
study.  Treatment sites were asked to prospectively collect and record clinical data on 
women aged 16 years and over with a diagnosis of invasive carcinoma of the breast or 
ductal carcinoma in-situ (DCIS) undergoing mastectomy surgery with IR or primary DR 
following a previous mastectomy, and to obtain written consent from eligible women to allow 
them to be sent follow up questionnaires. 
 
Reconstructive procedure types 
We compared six different surgical techniques: tissue expander or breast implant alone; 
pedicled latissimus dorsi flap combined with an expander or implant (LD with 
implant/expander); LD flap alone (autologous LD); pedicled transfer of a transverse rectus 
abdominis myocutaneous flap (pedicled TRAM); free tissue transfer of this flap (free TRAM); 
or a free tissue transfer of a similar flap without the underlying muscle, based on the deep 
inferior epigastric artery perforator or superficial inferior epigastric artery (DIEP or SIEA).  
The remaining patients had a flap of skin and fat with or without muscle taken from the upper 
or lower buttock or inner thigh regions (SGAP, IGAP or TUG), but they were excluded from 
our analyses due to the extremely small numbers enrolled.   
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Clinical data collection 
A range of data items were recorded by clinicians for each patient.  These included details of 
surgical procedures, patient clinical and sociodemographic characteristics, and consent 
status.  The full dataset is available at https://www.rcseng.ac.uk/standards-and-
research/research/clinical-effectiveness-unit/ 
 
Patient questionnaires 
The post-reconstruction questionnaires addressed patient satisfaction with their breast area 
appearance (16 items with an additional 2 for implant patients), which we believe to be 
synonymous with aesthetic outcome from the patient’s perspective, along with emotional 
well-being (10 items), physical well-being (16 items), sexual well-being (6 items), and the 
outcomes of surgery (7 items) respectively.  The scales were derived from the Breast-Q,2 
and were pre-tested with English breast cancer patients by the authors prior to their use to 
ensure that there were no issues with language, comprehension or acceptability.  Copies of 
the full questionnaires are available at https://www.rcseng.ac.uk/standards-and-
research/research/clinical-effectiveness-unit/ 
 
Questionnaire administration and collection 
Clinicians were asked to obtain consent from any eligible women at the time of surgery to 
allow follow-up questionnaire administration.  The questionnaires were sent to consented 
patients at their home address 18 months after surgery by a co-ordinating team of 
researchers that did not include the treating hospitals or clinicians, once the team had 
confirmed the patient was still alive by cross-checking their details against mortality data 
held by the National Strategic Tracing Service (NSTS).  A prepaid envelope was enclosed to 
facilitate the return of the completed questionnaire.  Questionnaires were marked only with a 
unique numeric patient identifier.  Non-respondents were sent a single reminder letter and 
an additional copy of the questionnaire at a five week interval. 
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Statistical analysis and multiple linear regression model 
Patients’ responses were entered into a database and then transferred to a bespoke Q-
Score software package to calculate scores for each Breast-Q scale, with 0 the lowest and 
100 the highest possible scores.2  Patient scores were linked to their associated clinical data 
using their unique numeric identifier.   
 
Separate linear multiple regression models were developed for the immediate and delayed 
reconstruction patient groups, and were used to predict the outcome scores for each Breast-
Q scale (dependent variables) based on patient characteristics and reconstructive procedure 
type.  The preliminary models included only patients with complete outcome and case-mix 
data, and were constructed using a backward stepwise process with variables dropped from 
the models if the strength of their association with an outcome was weak (Wald test for 
variable inclusion, p-value<0.05).  Variables were included in continuous or categorical 
format depending on their type.  The case-mix variables included sociodemographic items 
(age, a geographically assigned measure of socioeconomic deprivation, and hospital of 
treatment), patient factors known to affect subsequent morbidity (smoking status, body mass 
index, diabetes status, American Society of Anaesthesiologists grade, Eastern Cooperative 
Oncology Group performance status), and tumour characteristics (invasive status and 
Nottingham Prognostic Index).18-21  Deprivation in England is measured by the government 
using seven distinct domains or indicators of poverty (income; employment; education, skills 
& training; health; crime; barriers to housing and services; living environment), that are 
weighted before a deprivation score and rank are produced for each geographical area 
(super output area or SOA, a small local population of a few thousand people).  
 
The Eastern Cooperative Oncology Group (ECOG) functional status categorical scoring 
system is an American measure used internationally to measure the functional status of 
patients undergoing cancer treatments. It is also known as the WHO or Zubrod score. 
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The models were then used to produce adjusted means and confidence intervals for each 
scale score, by procedure type, which demonstrated the effect size.  Finally, the Wald test 
was undertaken for the type of reconstructive procedure to examine the heterogeneity of 
outcomes across different types of reconstruction and determine whether or not the 
differences in means were due to chance alone.     
 
All statistical tests were two-sided and p-values less than 0.05 were considered to represent 
a statistically significant result.  All statistical analyses were undertaken using STATA/MP 14 
(Stata Corporation, College Station, Texas, US) and Microsoft Excel software.   
 
Results 
 
Patient population 
Within the study cohort, 3,349 patients underwent IR.  Of these, 43 did not have their 
consent status for the follow up study recorded, 35 were deemed incapable of completing a 
written questionnaire in English and 1,148 were not asked to participate due to difficulties 
with the recruitment process at some hospitals.  Of the remaining 2,123 women, 1,939 gave 
their consent and 1,528 returned a completed questionnaire.  After excluding 144 women for 
whom complete case-mix data was not available, responses from 1,384 were included in our 
final analyses.  Questionnaires were completed 586 days after surgery, on average, with an 
interquartile range of 30 days. 
 
There were 1,714 patients who underwent DR.  Of these, 9 did not have their consent status 
for the follow up study recorded, 6 were deemed incapable of completing a written 
questionnaire in English and 609 were not asked to participate.  Of the remaining 1,090 
asked to participate, 984 gave their consent and 761 retuned questionnaires.  A further 28 
patients were excluded due to incomplete case-mix data; this left 733 for our final analyses.  
The mean length of time between a patient’s mastectomy and their subsequent DR 
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procedure was, on average, 2.8 years (range 0 to 32 years).  There were small differences 
in the mean time to DR by procedure type, varying from 2.4 years (LD flap with implant) to 
2.9 (free flap) and 3.0 years (implant/expander-only) respectively.  Questionnaires were 
completed 582 days after surgery, on average, with an interquartile range of 26 days.  Table 
1 summarises the consent and response rates for the different reconstruction techniques.    
 
Patient characteristics across the surgical groups 
Table 2 displays the sociodemographic and clinical characteristics of the women who 
underwent each type of procedure.  Patients undergoing different procedures were generally 
similar.  Those characteristics that were significantly associated with the outcomes under 
investigation were included in the two separate multiple linear regression models used 
subsequently to derive final case-mix adjusted scores for the respective patient groups.  
During the model development process the characteristics significantly associated with 
outcomes were ethnicity, deprivation level, American Society of Anaesthesiologists (ASA) 
grade and tumour burden for immediate reconstruction patients, and ethnicity, Eastern 
Cooperative Oncology Group (ECOG) score and diabetes status for those undergoing 
delayed reconstruction.  The other characteristics examined (including age, radiotherapy, 
chemotherapy, smoking status and body mass index) were not independently associated 
with outcomes and were not therefore included in the final models.  The IR patients were of 
similar age and functional status to those undergoing DR, but were less likely to be from a 
white ethnic group or the most deprived quintile, or to have a high ASA grade or diabetes.  
IR patients were also much more likely to have a low tumour burden (DCIS or low risk 
invasive). 
  
Breast-Q scores for each procedure 
Figure 1 presents the IR and DR procedure-specific unadjusted mean scores for each of the 
five Breast-Q scales, along with the associated 95% confidence intervals.   
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With respect to breast area appearance, in the IR group women who underwent a pedicled 
TRAM procedure had the highest outcome scores.  However, the sample size for this group 
was relatively small (n=34) and thus the precision associated with this estimate is relatively 
poor.  The other patient groups who underwent a flap reconstruction (with or without implant) 
also had relatively high scores.  The lowest breast area appearance scores were associated 
with patients who underwent expander or implant-only reconstruction. 
 
In the DR group, free TRAM flaps, DIEP flaps and then the other types of flap-based 
reconstruction (with or without implant) were associated with the highest breast area 
appearance scores.  Again, the expander or implant-only patient group had the lowest 
scores. 
 
After adjustment for patient characteristics, there were persistent differences in the 
outcomes achieved by the procedure groups, with the exception of physical well-being.  
Table 3 shows the adjusted differences in the mean scores for each scale, using the 
expander / implant group as the reference category.  In both the IR and DR settings, all flap-
based procedures resulted in higher scores on all scales other than physical well-being.  The 
only exception to this pattern was for the IR pedicled TRAM group.     
 
Discussion 
 
Key findings 
Women who underwent reconstruction tended to be satisfied with the results of the 
procedure, with mean overall satisfaction scores of 71.1 (95% CI 69.8 to 72.4) for IR 
procedures and 79.3 (95% CI 77.7 to 81.0) for DR procedures.  
 
Patients who underwent autologous reconstruction reported higher scores than those 
women who had an expander or implant alone, in both the IR and DR settings, across four of 
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the five scales.  For immediate procedures, the size of these differences was typically 
between 1 and 7 points.  For delayed procedures, the difference between the scores tended 
to be between 7 and 15 points.22  To interpret the magnitude of these differences it is useful 
to compare to a cohort of patients who underwent mastectomy alone over the same period 
at the same group of hospitals.16  These patients recorded a mean score of 56 on the breast 
area appearance scale, which is similar to the mean unadjusted score recorded for implant-
only patients recorded in this study but between 8 and 21 points lower than that recorded for 
patients undergoing autologous IR procedures.  A similar pattern was seen for emotional 
well-being (1 point difference for implant-only; 5 to 16 point difference for autologous 
procedures) and sexual well-being (7 point difference for implant-only; 13 to 28 point 
difference for autologous procedures), while physical well-being scores were similar in those 
who underwent mastectomy or any form of IR.  There is no agreed definition of what 
constitutes a clinically important difference for the Breast-Q scales used in our study but a 
difference of approximately 10 points on each scale may be taken to be equivalent to a 
moderate effect size using Norman’s standard formula of one half a standard deviation.23  
 
We would caution that these results should not be interpreted as a prescriptive indication in 
favour of one set of procedures over another.  We were not able to collect data on women’s 
perspectives on what might have led them to select one type of reconstruction over another.  
Consequently, we have no way of taking into account their baseline expectations or the 
influence of their preferences for the level of surgical insult they were willing to endure.  We 
therefore suggest that the results should only be used to inform women of the outcomes they 
might expect to achieve with different treatment scenarios and should be employed 
alongside information about the surgical approach, complication rates and recovery time. 
 
Strengths and limitations 
Our study had a number of strengths.  First, we used specifically developed and previously 
validated outcome measures that were distributed centrally at a standardised follow up 
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interval of 18 months, to ensure that the great majority of women had completed any 
adjuvant treatments and secondary reconstructive procedures required.2,17,22,24,25  Second, 
we examined outcomes for a national population that was recruited prospectively, with 
explicit written consent obtained prior to inclusion.  Third, we had excellent response rates of 
close to 80%.  Fourth, we included women with failed reconstructive procedures within the 
study to minimise bias.  Fifth, to minimise the risk of confounding we undertook robust case-
mix adjustment within a multiple linear regression model that included all factors that 
significantly affected our study outcomes.  This adjustment had little effect on the outcome 
scores of each scale, suggesting that our procedure-specific comparisons were safe and 
robust. 
 
There were also some weaknesses.  While the overall sample of around 1,500 IR and 700 
DR patients was large compared to other studies in this field, the size of certain subgroups 
(e.g. those who had a pedicled TRAM flap) was relatively small, with wide confidence 
intervals and an increased risk of sampling bias.  
 
Next, not all eligible women were asked to participate in the study and it was not possible to 
estimate the recruitment rates for specific procedures.  It is possible that recruitment was 
higher for certain procedures and that this has introduced a bias to the estimated outcomes 
we have recorded.  However, there is no obvious reason why recruitment may have been 
higher for certain procedures and the diffusion of patients in different procedure groups 
across a very large number of hospitals makes it unlikely that variable recruitment introduced 
a systematic error to our findings.   
 
There was also the potential for heterogeneity of outcome across the large number of 
hospitals we included in the study.  However, we included the identity of these organisations 
as a variable in our regression models to adjust for any organisation-level clustering. 
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Finally, our comparisons do not include recently developed reconstructive techniques such 
as lipomodelling and acellular dermal matrix and dermal sling procedures that were not 
widely used during the study period. 
 
Interpretation of our findings 
This study is consistent with a growing body of evidence that reconstruction using patients’ 
own tissues is associated with better aesthetic outcomes than reconstruction using only an 
implant or expander. 6-14  There are a number of explanations for why autologous procedures 
are associated with superior aesthetic outcomes. 
 
An implant or expander on its own can replace the volume that has been lost during 
mastectomy but cannot fully reconstitute the breast mound with respect to its shape or 
position on the chest wall.  They are also static devices that will not adjust or change 
automatically with a patient’s body habitus.  Implants generally do not produce natural ptosis 
of the breast as they adhere to the chest wall and cannot be positioned to extend below the 
inframammary fold, unlike native breast tissue or a flap.  An implant can usually only be 
placed safely under mastectomy skin if covered by an additional layer, whether muscle or 
alternatively an acellular dermal matrix or dermal flap or sling.  If not using a flap, the 
standard approach is to place an expander under the pectoralis major and stretch the 
muscle out, as otherwise the muscle is inadequate in terms of coverage and leaves the 
lower pole of the implant exposed.  Using a sub-muscular implant or expander placement 
without breast tissue to provide additional cover means that the final breast mound shape 
achieved is difficult to control and predict.  Although this may be less of an issue with 
bilateral reconstruction, our study included only those women with unilateral reconstruction 
whose contralateral breast was preserved. 
 
Finally, implants lead the body to form a capsule of scar tissue around them.  This capsular 
tissue contracts in a significant proportion of patients, more commonly following 
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radiotherapy.  An implant with a contracted capsule sits proud on the chest wall and may 
cause pain in addition to distortion.  These implants may need to be removed or exchanged 
with capsule management (excision or release) at more frequent intervals for those women 
who are worst affected; a lifetime of additional procedures for some. 
 
In contrast, using fat with or without muscle and skin from the back, abdomen, buttock or 
thigh (a flap) has a number of advantages.  First, because they consist of the patient’s own 
tissues they grow and shrink with the patient, and the contralateral breast, as their weight 
changes.  Second, as flap constituents are similar to the breast tissue excised, they are 
better able to mimic the contralateral breast’s natural shape, ptosis and movement.  Third, 
infection risk is much lower as the tissues have an intact or restored blood supply and can 
respond to pathogens in a normal manner.  Fourth, there are no capsular issues, and the 
reconstruction, if primarily successful, is definitive and lasts for life in most cases without the 
need for replacement.   
 
The principal disadvantage of flap-based reconstruction is the need for a flap donor site that 
will inevitably be left with a scar, and sometimes with a contour defect, muscle weakness or 
bulge, sensory changes or another type of longstanding or permanent morbidity.  Another 
disadvantage is that these procedures are usually longer in duration and may expose 
patients to a higher risk of distant and systemic complications.  
 
If an implant is used in combination with a flap (e.g. in the latissimus dorsi with implant 
group) the flap provides many of the advantages mentioned above, and ameliorates some of 
the aesthetic limitations of implant-only reconstruction by providing soft tissue coverage and 
a more natural shape, while allowing definitive implant placement without the need for a 
temporising expander.  This is reflected in the high outcomes scores associated with such 
procedures, which in this study were comparable to autologous flap reconstruction.  
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However, the patient is left with both a degree of donor site morbidity and the need for 
capsule management and implant replacement over time.      
 
Implications for clinical practice 
Clinicians should ensure that women are provided with appropriate and adequate 
information about all breast reconstruction options as part of the decision-making process, 
including our principal finding that autologous procedures are associated with better 
aesthetic outcomes. 
 
Our case-mix findings suggest that although there may be some selection of reconstructive 
procedure type by indication, the populations undergoing different procedures are broadly 
comparable.  This suggests that many women who undergo implant-based reconstruction 
may also be suitable for flap-based reconstruction.  While not all women would choose 
autologous procedures due to their greater complexity, longer duration, donor site morbidity 
and higher overall complication rates, they should be informed that implant-based 
procedures are not without risks, particularly implant failure,16 and have now been shown to 
be associated with lower patient-reported outcome scores.   
 
Conclusion 
Women who accessed autologous techniques tended to report greater satisfaction with their 
reconstruction than those who had an expander or implant.  We recommend that clinicians 
act on our findings by providing all patients with appropriate written and verbal information 
regarding the full range of reconstructive options, including those not available at their 
treating hospital, and their associated patient-reported outcomes.   
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Table 1 – Patient recruitment and response rates associated with the different reconstructive procedure groups, in both immediate 
and delayed reconstruction settings 
  
Expander / 
Implant 
 
LD with 
implant or 
expander 
 
 
Autologous 
LD 
 
 
Pedicled 
TRAM 
 
 
Free TRAM 
 
 
DIEP / SIEA 
 
Overall 
Immediate reconstruction              
Number of patients in study  1242 
 
729 
 
850 
 
82 
 
92 
 
354 
 
3349 
Number (%) of patients asked to 
participate 
759 (61.1) 453 (62.1) 594 (69.9) 52 (63.4) 60 (65.2) 222 (62.7) 2140 
Number (%) of patients who gave their 
consent 
681 (89.7) 414 (91.4) 520 (87.5) 41 (78.8) 57 (95.0) 204 (91.9) 1917 
Number (%) of patients who returned a 
questionnaire 
522 (76.7) 330 (79.7) 430 (82.7) 37 (90.2) 44 (77.2) 165 (80.9) 1528 
Number of patients who returned a 
questionnaire and had complete clinical 
data 
 
475   284   402   34   36   153   1384 
Delayed reconstruction              
Number of patients in study  280 
 
434 
 
356 
 
90 
 
191 
 
363 
 
1714 
Number (%) of patients asked to 
participate 
169 (60.4) 253 (58.3) 251 (70.5) 58 (64.4) 115 (60.2) 248 (68.3) 1094 
Number (%) of patients who gave their 
consent 
149 (88.2) 233 (92.1) 216 (86.1) 49 (84.5) 104 (90.4) 222 (89.5) 973 
Number (%) of patients who returned a 
questionnaire 
109 (73.2) 183 (78.5) 166 (76.9) 35 (71.4) 85 (81.7) 183 (82.4) 761 
Number of patients who returned a 
questionnaire and had complete clinical 
data 
 
104   176   160   35   83   175   733 
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Table 2 – Patient characteristics by reconstructive procedure type 
  Expander/ 
Implant 
LD with 
implant or 
expander 
Autologous 
LD 
Pedicled 
TRAM 
Free TRAM DIEP/ 
SIEA 
Total 
Immediate reconstruction      
Number of responders 475 284 402 34 36 153 1,384 
Age (years) Median 51 51 53 52 51.5 51 51 
 IQR 15 14 13 12 14.5 12 14 
Ethnicity / 
% 
White 
 
85.1 84.5 83.3 97.1 88.9 81.1 84.4 
 Non-white 
 
3.4 4.6 4.0 0.0 0.0 9.2 4.3 
 Not known /  
not stated 
 
11.6 10.9 12.7 2.9 11.1 9.8 11.3 
Index of 
multiple 
deprivation 
(IMD) 
Quintile / 
% 
1 (least deprived) 28.8 34.5 28.1 32.4 36.1 33.3 30.6 
2 20.0 25.4 26.4 17.7 33.3 23.5 23.6 
3 22.1 16.9 21.9 8.8 22.2 21.6 20.6 
4 14.1 13.7 12.7 29.4 2.8 12.4 13.5 
5 (most deprived) 15.0 9.5 11.0 11.8 5.6 9.2 11.7 
ASA grade 
/ % 
1 69.1 76.4 73.1 70.6 72.2 69.9 72.0 
 2 28.0 23.2 26.1 29.4 25.0 30.1 26.7 
 3 or 4 3.0 0.4 0.8 0.0 2.8 0.0 1.4 
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ECOG 
Status / % 
0 90.9 93.3 92.0 91.2 94.4 96.1 92.4 
 1 7.0 6.4 7.5 8.8 5.6 3.3 6.6 
 2 plus 2.1 0.4 0.5 0.0 0.0 0.7 1.0 
Diabetes 
status / % 
Diabetic 
 
1.7 1.1 1.5 2.9 2.8 1.3 1.5 
Tumour 
burden / %  
DCIS 26.5 27.8 32.3 41.2 36.1 26.8 29.1 
 Low NPI 36.2 37.7 30.1 23.5 27.8 26.8 33.2 
 Intermediate NPI 24.0 22.9 21.4 26.5 16.7 28.8 23.4 
 High NPI 13.3 11.6 16.2 8.8 19.4 17.7 14.3 
Delayed reconstruction      
Number of responders 104 176 160 35 83 175 733 
Age (years) Median 55 50.5 52 52 50 51 51 
 IQR 11.5 14 14 14 11 13 14 
Ethnicity / 
% 
White 
 
92.3 90.9 89.4 88.6 79.5 91.4 89.5 
 Non-white 
 
1.9 2.3 3.1 0.0 6.0 2.9 2.9 
 Not known /  
not stated 
5.8 6.8 7.5 11.4 14.5 5.7 7.6 
Index of 
multiple 
deprivation 
(IMD) 
Quintile / 
1 (least deprived) 24.5 23.2 21.2 34.4 35.0 30.2 26.5 
2 28.4 22.0 23.8 18.8 21.3 25.0 23.8 
3 18.6 20.8 19.9 12.5 17.5 19.2 19.2 
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% 4 15.7 19.1 14.6 15.6 17.5 12.2 15.6 
5 (most deprived) 12.8 14.9 20.5 18.8 8.8 13.4 14.9 
ASA grade 
/ % 
1 66.4 59.1 70.0 77.1 51.8 68.6 64.8 
 2 28.9 37.5 28.8 22.9 44.6 30.9 32.9 
 3 or 4 4.8 3.4 1.3 0.0 3.6 0.6 2.3 
ECOG 
Status / % 
0 88.5 90.3 91.3 91.4 92.8 95.4 91.8 
 1 7.7 9.7 7.5 8.6 7.2 4.6 7.4 
 2 plus 3.9 0.0 1.3 0.0 0.0 0.0 0.8 
Diabetes 
status / % 
Diabetic 
 
1.9 2.3 3.8 2.9 1.2 3.4 2.7 
Tumour 
burden / %  
DCIS 15.8 8.5 19.2 6.9 8.2 11.7 12.6 
 Low NPI 37.6 25.5 19.9 31.0 30.1 29.2 31.4 
 Intermediate NPI 26.7 38.2 29.8 31.0 30.1 29.2 31.4 
 High NPI 19.8 27.9 31.1 31.0 37.0 32.5 29.6 
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Table 3 – Adjusted mean difference in Breast-Q scores by type of reconstruction, with expander / implant as reference, for each 
immediate and delayed reconstruction procedure type 
 
Immediate reconstruction patients 
Reconstruction type Breast area appearance Emotional well being Physical well being Sexual well being Satisfaction with 
outcome 
 Mean  
diff 
95% CI Mean 
diff 
95% CI Mean 
diff 
95% CI Mean 
diff 
95% CI Mean 
diff 
95% CI 
Expander/implant 
 
Reference          
LD with implant or 
expander 
8.2 5.3 to 11.1 7.7 4.6 to 10.8 0.7 -1.5 to 2.9 5.8 2.0 to 9.6 6.2 2.3 to 10.1 
Autologous LD 
 
8.6 5.4 to 11.8 4.9 1.8 to 8.0 -1.4 -3.2 to 0.4 4.3 0.2 to 8.4 3.0 -0.6 to 6.6 
Pedicled TRAM 
 
21.2 11.0 to 31.4 14.1 6.8 to 21.4 4.6 0.4 to 8.8 21.1 7.2 to 35.0 17.5 10.7 to 24.2 
Free TRAM 
 
5.2 0.2 to 10.2 2.6 -2.6 to 7.8 -1.3 -4.6 to 1.9 5.1 -2.1 to 12.4 3.5 -1.3 to 8.4 
DIEP/SIEA 
 
9.3 5.6 to 13.1 5.9 2.2 to 9.6 1.4 -0.5 to 3.4 7.1 2.3 to 11.8 4.3 -0.8 to 9.3 
Wald test of 
difference – p-value 
p<0.0001 p<0.0001 p=0.0074 p=0.0030 p=0.0001 
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Table 3 (continued) 
Delayed reconstruction patients 
Reconstruction type Breast area appearance Emotional well being Physical well being Sexual well being Satisfaction with 
outcome 
 Mean  
diff 
95% CI Mean 
diff 
95% CI Mean 
diff 
95% CI Mean 
diff 
95% CI Mean 
diff 
95% CI 
Expander/implant 
 
Reference          
LD with implant or 
expander 
9.5 4.7 to 14.3 8.2 2.6 to 13.8 -1.4 -6.4 to 3.6 7.1 -1.9 to 16.1 7.9 2.1 to 13.6 
Autologous LD 
 
11.7 6.1 to 17.2 7.1 0.7 to 13.6 -0.4 -4.3 to 3.6 4.6 -5.2 to 14.4 8.0 1.0 to 15.0 
Pedicled TRAM 
 
9.4 2.6 to 16.2 6.2 -2.6 to 15.0 -1.7 -8.7 to 5.3 5.7 -7.8 to 19.1 2.8 -6.3 to 11.8 
Free TRAM 
 
19.2 12.9 to 25.5 10.8 3.3 to 18.4 -0.1 -4.9 to 4.6 15.3 3.6 to 27.1 14.9 8.1 to 21.8 
DIEP/SIEA 
 
13.8 8.2 to 19.5 12.1 5.5 to 18.7 4.0 -0.2 to 8.2 12.0 1.0 to 23.0 13.9 7.5 to 20.2 
Wald test of 
difference – p-value 
p<0.0001 p=0.0054 p=0.0084 p=0.0211 p<0.0001 
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Figure 1 – Forest plot of unadjusted mean scores for each Breast-Q scale following immediate and delayed reconstruction, with 
associated 95% confidence intervals 
 
 
